Cannabidiol Market Assessment, By Species [Indica, Sativa, Hybrid], By Route of Administration [Oral, Topical, Others], By Form [Oils, Capsules, Tinctures], By Therapeutic Application [Cancer, Migraine, Epilepsy, Anxiety and Depression, Others], By End-us

Cannabidiol Market Assessment, By Species [Indica, Sativa, Hybrid], By Route of Administration [Oral, Topical, Others], By Form [Oils, Capsules, Tinctures], By Therapeutic Application [Cancer, Migraine, Epilepsy, Anxiety and Depression, Others], By End-user [Pharmaceutical Companies, Hospital Pharmacies, Online Pharmacies, Retail Stores, Research and Development Centers, Others], By Region, Opportunities and Forecast, 2017-2031F

Global cannabidiol market is projected to witness a CAGR of 18% during the forecast period 2024-2031, growing from USD 8.04 billion in 2023 to USD 30.22 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in the global cannabidiol market is being driven by various factors such as increased medicinal application of CBD in the healthcare industry and increased research and development by leading players to study the potential benefits of CBD in different medical conditions. Growing acceptance among people regarding the safe usage of CBD for health conditions such as epilepsy is leading to the growth of this market globally. Increased legalization of CBD across different countries is enhancing the interest of public and private organizations in investing in the cannabidiol market. The presence of several top players, new companies, and collaborative ventures such as mergers and acquisitions, partnerships, distribution agreements, and frequent new product launches are driving the growth of the global cannabidiol market.

The global cannabidiol market is undergoing significant growth due to the increasing application of CBD for medicinal purposes such as anxiety, depression, chronic pain, and epilepsy. CBD is widely used by the pharmaceutical industry as CBD oils, capsules, and topical creams, due to its huge potential in providing therapeutical advantages. As a result, several public and private organizations are increasingly investing in research and development activities to find out more therapeutical benefits of CBD. Over the years, there has been an increased acceptance of CBD usage for medicinal purposes among patients and healthcare providers, leading to a growing demand for the CBD market.

A favorable regulatory framework plays a crucial role in enhancing the global CBD market. There has been increased legalization of the usage of CBD for medicinal purposes across different countries. The act is enhancing and expanding the CBD market at a global level. Moreover, frequent collaboration activities such as mergers and acquisitions, partnership agreements between the companies, consistent innovative product launches by the key market players, along with new entrances, further propels the global cannabidiol market. In December 2023, Rare Cannabinoid Company announced the launch of THC + THCV Uplift Gummies. This product has been launched for the United States consumers to increase focus, energy, and control hunger.

Increasing Prevalence of Mental Health Problems

There has been a surge in demand for cannabidiol due to the rising number of mental illnesses such as anxiety and depression among the global population. Mental health conditions are not uncommon these days and affect a larger section of people from all over the world. The World Health Organization states that mental disorders such as depression have become a common health condition in today’s life. Globally, around 3.8% of the population is affected by depression, includes 5% of adults and 5.7% of people aged 60 years and above.

WHO states that, globally, there are around 280 million people who suffer from depression. Depression is more common among women compared to men. Globally, 10% of pregnant and post-partum women experience depression every year. WHO states that every year more than 700,000 people die due to suicide. Several studies have shown the potential of CBD in managing depression and anxiety, which has substantially led to improvement in the health condition of the people. Hence, many organizations are incorporating CBD for developing CBD-based products.

Favorable Regulatory Framework

With the growing demand for CBD-based products, there has been consideration within the regulatory bodies such as FDA, to improve and bring new regulatory pathways to support the ethical and safe use of CBD-based products in the healthcare industry. In January 2023, the Food and Drug Administration in the United States announced that it is now re-evaluating the regulatory framework for goods containing cannabidiol. The FDA has determined that the current regulatory frameworks for foods and supplements do not apply to CBD and that a new regulatory approach is required to initiate a compromise between the requirement for consumer safety and people's desire to have access to CBD products. To create a new cross-agency approach to the regulation of these items, the FDA is ready to collaborate with Congress. This favorable change in the current regulatory systems is expected to accelerate the development of cannabidiol.

Consumption of CBD Oil is Witnessing Significant Demand

Among the form segments, CBD oil segment holds a significant market share in the global cannabidiol market. In comparison with other forms of cannabidiol, CBD oil has vast application areas such as in pain management, epilepsy, nutraceuticals and beauty. CBD oils are legal and easy to access, which makes it highly popular among manufacturers and consumers. Additionally, several leading players are launching CBD oils for various medical purposes in their product portfolio, which is enhancing the growth of the global cannabidiol market. For instance, in September 2023, Aurora Cannabis Inc., a Canada based medical cannabis company announced an expansion of its hemp-derived CBD portfolio in Brazil. The company is all set to launch full-spectrum, single-source 3% CBD oil, to cater to the need of the consumers in Brazil.

Application of CBD in Treating Epilepsy

Among the therapeutic application segment, CBD is widely used for the treatment of epilepsy and thus, the segment holds a significant market share in the overall global cannabidiol market. Cannabidiol has shown promising positive effects in the treatment of epilepsy, especially in certain epileptic syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. Regulatory bodies such as the European Medicines Agency and the U.S. Food and Drug Administration have approved CBD for use in certain epilepsy treatments.

Moreover, key market players are bringing new product launches in this segment to improve the health conditions of the patients, which is further accelerating the growth of the segment. In January 2023, Medical Marijuana, Inc. subsidiary “HempMeds Brasil” successfully launched two new CBD-based products in Brazil to help in the treatment process of epilepsy. HempMeds Brasil is authorized to provide its CBD-based products, under medical prescription to aid in the management of diseases such as epilepsy, Parkinson’s, chronic pain, and multiple sclerosis.

North America Dominates Global Cannabidiol Market

North America holds the largest share in global cannabidiol market, due to various factors such as the presence of major manufacturers including Medical Marijuana Inc. and Tilray Inc., increased acceptance among healthcare providers and people regarding using CBD-based products for medical conditions such as anxiety, depression, epilepsy, and pain management driving high demand for cannabidiol. Additionally, favorable laws regarding the usage of CBD products in most of the countries in North America are enhancing the growth of the market.

Medical Marijuana Inc., stated that in the United States, there are around 33 states, that have legalized safe usage of marijuana and there are more states that are expected to receive permission to legalize cannabinoid usage in the future. Consequently, along with the re-formation of federal law, it is expected that North America will further undergo tremendous growth in the cannabidiol market and will maintain its leadership in the forecast period as well.

Future Market Scenario (2024 – 2031F)

The global cannabidiol market is expected to grow in the future due to multiple factors. The increasing prevalence of anxiety and depression among the population has enhanced the company’s focus in developing CBD-based products that can help with relieving mental stress among the users. Increased acceptance among healthcare providers regarding the capabilities of CBD in the treatment of anxiety, depression, and epilepsy has enabled pharmaceutical companies to increase investments in the market. There has been a surge in research and development activities in the market to further explore the potential benefits of CBD in patient treatments. Collaborative ventures among the companies, improved and supportive regulatory framework, and new entrants have spurred growth in the global cannabidiol market. According to an article published in the “Hartford Business Journal” many CBD companies are planning to start their operations in 2023 and 2024. Along with it, new retailers, manufacturers, and products are expected to enter the cannabidiol market, which will further assist in driving the market growth.

Key Players Landscape and Outlook

In cannabidiol market, several pharmaceutical companies are consistently establishing strategic partnerships, and distribution agreements, which play a pivotal role in driving the demand for cannabidiol products. These partnerships enable firms to gain informative insights regarding the market, take advantage of each other’s resources, markets, and technologies, and invest in research and development activities to bring advancements in the market. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expertise product development and contribute to the enduring and robust growth of the global market.

For instance, in August 2023, Medical Marijuana, Inc., announced that Kannaway, which is its subsidiary, completed acquisition of a Japan based network marketing company “EXfuse, LLC, dba KZ1”. The acquisition will expand the company’s business in Japan and the KZ1’s premium products such as nootropics-based products enhancing the company’s CBD product portfolio. The partnership further aims to bring innovative product launches in their various business segments such as natural health, beauty, and CBD products.

1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Cannabidiol Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1. By Value
4.1.2. By Volume
4.2. By Species
4.2.1. Indica
4.2.2. Sativa
4.2.3. Hybrid
4.3. By Route of Administration
4.3.1. Oral
4.3.2. Topical
4.3.3. Others
4.4. By Form
4.4.1. Oils
4.4.2. Capsules
4.4.3. Tinctures
4.5. By Therapeutic Application
4.5.1. Cancer
4.5.2. Migraine
4.5.3. Epilepsy
4.5.4. Anxiety and Depression
4.5.5. Others
4.6. By End-user
4.6.1. Pharmaceutical Companies
4.6.2. Hospital Pharmacies
4.6.3. Online Pharmacies
4.6.4. Retail Stores
4.6.5. Research and Development Centers
4.6.6. Others
4.7. By Region
4.7.1. North America
4.7.2. Europe
4.7.3. Asia-Pacific
4.7.4. South America
4.7.5. Middle East and Africa
4.8. By Company Market Share (%), 2023
5. Global Cannabidiol Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1. Market Size & Forecast By Value By Volume
5.1.2. By Species Indica Sativa Hybrid
5.1.3. By Route of Administration Oral Topical Others
5.1.4. By Form Oils Capsules Tinctures
5.1.5. By Therapeutic Application Cancer Migraine Epilepsy Anxiety and Depression Others
5.1.6. By End-user Pharmaceutical Companies Hospital Pharmacies Online Pharmacies Retail Stores Research and Development Centers Others
5.1.7. United States* Market Size & Forecast By Value By Volume By Species Indica Sativa Hybrid By Route of Administration Oral Topical Others By Form Oils Capsules Tinctures By Therapeutic Application Cancer Migraine Epilepsy Anxiety and Depression Others By End-user Pharmaceutical Companies Hospital Pharmacies Online Pharmacies Retail Pharmacies Research and Development Centers Others
5.1.8. Canada
5.1.9. Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. United Kingdom
5.2.5. Netherlands
5.2.6. Spain
5.2.7. Turkey
5.2.8. Poland
5.3. Asia-Pacific
5.3.1. India
5.3.2. China
5.3.3. Australia
5.3.4. Vietnam
5.3.5. South Korea
5.4. South America
5.4.1. Brazil
5.4.2. Argentina
5.5. Middle East & Africa
5.5.1. South Africa
6. Market Mapping, 2023
6.1. By Species
6.2. By Route of Administration
6.3. By Form
6.4. By Therapeutic Application
6.5. By End-user
6.6. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.5.1. Supplier Power
7.5.2. Buyer Power
7.5.3. Substitution Threat
7.5.4. Threat from New Entrant
7.5.5. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Charlotte’s Web, Inc.
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Medical Marijuana, Inc.
13.3. Jazz Pharmaceuticals plc.
13.4. Aurora Cannabis Inc.
13.5. Hemp Synergistics LLC
13.6. Canopy Growth Corporation
13.7. Isodiol International Inc.
13.8. Gaia Botanicals, LLC, d/b/a Bluebird Botanicals
13.9. CV Sciences, Inc.
13.10. High Tide Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings